Skip to main
MRUS
MRUS logo

Merus (MRUS) Stock Forecast & Price Target

Merus (MRUS) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 13%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Merus NV's recent acquisition offer by Genmab for $97 per share, representing a significant 41% premium, enhances the company's prospects by effectively mitigating FDA-related regulatory concerns. The strategic integration into Genmab's late-stage pipeline is expected to foster multiple proprietary product launches by 2027, thus positioning Merus for substantial long-term growth. Moreover, with the promising potential of petosemtamab, which is projected to generate at least $1 billion in revenue by 2029 and has already received two FDA Breakthrough Therapy Designations, the outlook for Merus's stock remains positive as it leverages its bispecific antibody expertise in collaboration with a leading biotechnology firm.

Bears say

Merus NV's stock outlook has been downgraded to Neutral following the announcement of an all-cash acquisition by Genmab, reflecting concerns over the transaction's implications for Merus's valuation. The proposed acquisition price of $97 per share signifies a significant reduction in market confidence, leading to a decrease in the price target from $109 to $97. Additionally, Genmab's financing strategy, which includes taking on $5.5 billion in non-convertible debt, raises further concerns about the financial stability and future growth prospects of Merus NV in the competitive immuno-oncology landscape.

Merus (MRUS) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 13% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merus (MRUS) Forecast

Analysts have given Merus (MRUS) a Hold based on their latest research and market trends.

According to 15 analysts, Merus (MRUS) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merus (MRUS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.